[Progress in therapy and diagnosis: Hypercalcemia due to parathyroid hormone-related protein producing neoplasms].
Tanaka
Yoshiya
Y
Okada
Yosuke
Y
D000818:Animals; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D002116:Calcitonin / Q000008:administration & dosage; D004164:Diphosphonates / Q000008:administration & dosage; D005440:Fluid Therapy; D006801:Humans; D006934:Hypercalcemia / Q000209:etiology* / Q000628:therapy*; D009369:Neoplasms / Q000150:complications* / Q000378:metabolism*; D053244:Osteoprotegerin / Q000627:therapeutic use; D010257:Paraneoplastic Syndromes / Q000209:etiology* / Q000628:therapy*; D044162:Parathyroid Hormone-Related Protein / Q000096:biosynthesis* / Q000502:physiology; D011239:Prednisolone / Q000627:therapeutic use; D012964:Sodium / Q000008:administration & dosage; D049994:Sodium Potassium Chloride Symporter Inhibitors / Q000008:administration & dosage
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D053244:Osteoprotegerin; D044162:Parathyroid Hormone-Related Protein; D049994:Sodium Potassium Chloride Symporter Inhibitors; D002116:Calcitonin; D012964:Sodium; D011239:Prednisolone